Combination Immunosuppressive Therapy for Giant Cell Myocarditis

Intern Med. 2022 Oct 1;61(19):2895-2898. doi: 10.2169/internalmedicine.9112-21. Epub 2022 Mar 5.

Abstract

A 60-year-old woman with a history of hypothyroidism was referred to our hospital for shortness of breath and a left ventricular ejection fraction (LVEF) of 13%, which required continuous dobutamine injection with intra-aortic balloon pump support. An endomyocardial biopsy obtained from the right ventricle revealed an infiltration of giant cells and eosinophils, indicating giant cell myocarditis. In addition to heart failure treatment, combined immunotherapy with steroids, tacrolimus, and intravenous immunoglobulin was administered. Transthoracic echocardiography demonstrated a dramatic improvement in the LVEF after this therapy, and the patient was discharged home without symptoms on day 72.

Keywords: giant cell myocarditis; intravenous immunoglobulin therapy; tacrolimus.

Publication types

  • Case Reports

MeSH terms

  • Dobutamine
  • Female
  • Giant Cells / pathology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunosuppression Therapy
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Myocarditis* / diagnostic imaging
  • Myocarditis* / drug therapy
  • Stroke Volume
  • Tacrolimus
  • Ventricular Function, Left

Substances

  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Dobutamine
  • Tacrolimus